SALIM VIRANI to Angiotensin Receptor Antagonists
This is a "connection" page, showing publications SALIM VIRANI has written about Angiotensin Receptor Antagonists.
Connection Strength
0.495
-
Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease. Nephrol Dial Transplant. 2021 09 27; 36(10):1893-1899.
Score: 0.178
-
Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials. Cardiovasc Drugs Ther. 2016 Apr; 30(2):189-98.
Score: 0.122
-
Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure. Am J Cardiovasc Drugs. 2024 Jul; 24(4):481-504.
Score: 0.054
-
Understanding Prescribing Practices and Patient Experiences with Renin Angiotensin System Inhibitors Use in Chronic Kidney Disease: A Qualitative Study. Cardiorenal Med. 2024; 14(1):34-44.
Score: 0.052
-
Documented Adverse Drug Reactions and Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. Am J Nephrol. 2023; 54(3-4):126-135.
Score: 0.050
-
Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program. Circ Cardiovasc Qual Outcomes. 2019 11; 12(11):e005455.
Score: 0.039